gastrin inhibitory peptide gastric inhibitory peptide - Gastricinhibitory peptideexamples peptide Gastrin Inhibitory Peptide: A Key Regulator of Glucose Metabolism and Beyond

Gastricinhibitory peptidereleased by Gastrin inhibitory peptide (GIP), also known by its more descriptive name glucose-dependent insulinotropic polypeptide, is a fascinating 42-amino acid peptide hormone that plays a crucial role in regulating glucose metabolism and influencing various physiological processes within the human body.作者：RA Pederson·2016·被引用次数：35—GIP was shown to inhibit acid secretion in animal models, as well as stimulatinggastricsomatostatin secretion. However, its role in humangastricphysiology ... Synthesized and secreted by specialized neuroendocrine cells, primarily the K cells, located in the proximal small intestine, GIP is a member of the secretin family of hormones. Its discovery, initially as a factor in intestinal extracts that inhibited gastric motility and acid secretion, led to its early designation as "enterogastrone." However, subsequent research revealed a more nuanced and significant role, particularly in the context of nutrient intake and insulin secretion.Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose ...

The primary function of gastrin inhibitory peptide is as an incretin hormone. Incretins are gut hormones released in response to the ingestion of food, and they play a vital role in enhancing insulin secretion from the pancreatic beta cells. This effect is dose-dependent on glucose levels, meaning that GIP's ability to stimulate insulin release is significantly amplified when blood glucose is elevated. This glucose-dependent insulinotropic polypeptide action is critical for maintaining glucose homeostasis after a meal. Alongside glucagon-like peptide-1 (GLP-1), GIP is considered one of the principal incretin hormones, collectively accounting for a substantial portion of the postprandial insulin response. This synergistic action between GIP and GLP-1 highlights their importance in the complex endocrine control of digestion and metabolism.

While its role in stimulating insulin secretion is well-established, the historical nomenclature of "gastrin inhibitory peptide" points to another important, albeit less potent, effect: the inhibition of gastric acid secretion. Studies have demonstrated that GIP can indeed inhibit carbachol-stimulated gastrin release, and under certain experimental conditions, it can also inhibit gastric acid secretion. However, in humans, this inhibitory effect on gastric acid secretion is considered relatively weak compared to its potent insulinotropic effectsGastric Inhibitory Peptide (GIP) (3-42), human. Furthermore, research has indicated that GIP may also stimulate gastric somatostatin secretion, adding another layer to its influence on digestive physiologyGastric Inhibitory Polypeptide - an overview.

The mechanism by which GIP exerts its effects involves binding to specific GIP receptors present on various target cells, most notably pancreatic beta cells.GIP and GLP‐1, the two incretin hormones - PubMed Central Upon binding, GIP initiates intracellular signaling cascades that lead to increased insulin synthesis and secretion. This process is fundamental to the "incretin effect," which describes the phenomenon where orally administered glucose elicits a greater insulin response than intravenously administered glucose, a difference largely attributed to the actions of incretin hormones like GIP and GLP-1[Tyr0] Gastric Inhibitory Peptide (23-42), Human 0.5 mg.

The physiological significance of gastrin inhibitory peptide extends beyond immediate glucose control.GIP receptor binds gastric inhibitory peptide Emerging research suggests that GIP also influences appetite and energy balance, further underscoring its multifaceted role in metabolic regulation. This has led to considerable interest in GIP as a therapeutic target for conditions such as type 2 diabetes and obesity. Indeed, dual-acting treatments targeting both GLP-1 and GIP receptors are being developed, showing promising results in weight loss and glycemic control.

However, the effectiveness of GIP signaling can be compromised in certain pathological statesOther articles wheregastric inhibitory peptideis discussed: human digestive system:Gastric inhibitory peptide: Secreted by the K cells, gastric .... For instance, the insulinotropic effect of GIP has been shown to be attenuated in patients with conditions like cystic fibrosis and pancreatic insufficiency, where the proper functioning of the pancreas is impaired. This highlights the intricate interplay between GIP and pancreatic healthGlucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt): An incretin hormone. Synonyms:Gastric Inhibitory Peptide, GIP. Purity: ≥95%..

The study of gastrin inhibitory peptide has evolved significantly since its initial discovery. Its initial identification as a factor inhibiting gastric secretion has given way to a deeper understanding of its profound impact on peptide hormone signaling and metabolic regulation. The scientific community continues to explore its various functions, including its potential role in stimulating glucagon secretion and its interactions with other gastrointestinal hormones like vasoactive intestinal peptide (VIP)(Synonyms: Gastric Inhibitory Peptide (GIP), human). The ongoing research into GIP and its receptor binding promises to unlock further therapeutic avenues for metabolic disorders. From its basic molecular structure, a 42 amino acid peptide hormone, to its complex physiological actions, gastrin inhibitory peptide remains a vital subject of study in endocrinology and metabolism. The various forms, such as GIP (1-42) and degraded forms like GIP (3-42) resulting from enzymes like DPPIV, are also subjects of scientific inquiry. The exploration of gastrin inhibitory polypeptide continues to reveal its central importance in maintaining metabolic health.